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What to do with “Surprise” N2?
Intraoperative Management of Patients with Non-small Cell
Lung Cancer
Frank Detterbeck, MD
There is debate about how patients should be managed when
malignant involvement of mediastinal lymph nodes is encountered
at the time of lung resection. A comprehensive review of the
literature demonstrates that differences in which outcomes are re-
ported and how extensively patients were staged preoperatively
explain much of the conflicting data. Certain negative and positive
prognostic factors can be defined, but in general the outcomes justify
proceeding with resection unless it is clear that disease will be left
behind. Reasonable arguments can be made that the approach should
include a mediastinal lymph node dissection and adjuvant therapy.
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The subject of intraoperative assessment and managementof unanticipated N2 involvement remains a confusing
area. The term “surprise N2” in this article refers to any
patient who is discovered to have N2 lymph node involve-
ment that was not suspected or documented preoperatively.
The data often seems to be conflicting, in part because the
patient populations vary (e.g., with respect to selection or the
extent of preoperative staging investigations). Because of
confusion about the data, approaches are often driven more
by underlying attitudes or assumptions. For example, some
take a simple, existentialistic approach that staging is rela-
tively unimportant because outcomes are determined by fate,
or at least factors about biologic behavior that we are not able to
predict. The implication of this attitude is that treatments other
than surgery are not useful. Others believe that dissemination of
lung cancer is primarily though lymphatic drainage in a progres-
sive manner, and therefore that resection of all potentially
involved nodes is crucial (and that the highest node is negative).
Others believe that nodal involvement is only useful as a prog-
nostic marker, representing a surrogate measure of whether a
tumor has developed the ability to grow significantly at other
sites. Proponents of this theory cite the fact that tumor cells
circulating in the bloodstream are quite frequent, even in node-
negative cancers, but do not always lead to disseminated metas-
tases. The data are not currently available to clearly prove or
refute such different underlying beliefs.
This article takes a purely pragmatic approach, and
discusses data that pertains to a number of practical clinical
questions that surgeons face. These include whether intraop-
erative nodal assessments should affect if resection is carried
out, whether it affects the extent of pulmonary resection,
including if there are special situations in which these ques-
tions should be answered differently. Finally, this article
considers the question whether there is a therapeutic benefit
to complete removal of all lymph nodes by means of a
mediastinal lymph node dissection (MLND), or whether the
extent of intraoperative node assessment merely contributes
to the accuracy of pathologic staging.
DOES MEDIASTINAL NODAL STATUS AFFECT
THE DECISION TO RESECT?
Mortality and Quality of Life (QOL)
Should the status of mediastinal nodes as assessed at
the time of thoracotomy affect the decision to proceed with a
resection? This question really comes down to an assessment
of the long-term survival versus the short-term mortality and
the effect on QOL. Answering the question is complex,
because the long-term survival, in particular, depends on
many factors and must be carefully considered.
There seems to be little difference in the perioperative
mortality of an exploratory thoracotomy versus a resection.
The average reported operative mortality after an exploratory
thoracotomy is 4% (0–7%).1–7 The average operative mor-
tality for pulmonary resection is approximately 4%,1 although
more recent series suggest it has decreased to about 2%.8–10
The data for QOL generally suggests that both short-
term and long-term QOL considerations have little impact on
intraoperative decision making. Most studies of perioperative
QOL have suggested that although short-term QOL is de-
creased by surgical resection, QOL returns to baseline by 6
months.1,11,12 There is no formal data concerning the short-
term morbidity of recovering from an exploratory thoracot-
omy versus a resection, but there is little reason to expect
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there to be a difference. Not undergoing a resection carries a
psychologic burden of loss of hope, whereas resection is
associated with loss of lung function, However, the majority
of studies11,13–16 demonstrate good long-term functional ca-
pacity even in patients with limited pulmonary reserve (with
only a few exceptions).17,18
Long-Term Survival
Long-term survival of patients with pN2 disease (i.e.,
postresection N2 disease) varies markedly according to pre-
operative factors and the extent of preoperative staging in-
vestigations. It must be noted that pathologic staging, as
officially defined, is staging done after a surgical resection.
Clinical staging involves any and all information available
before resection, and may be very extensive (e.g., including
mediastinoscopy) or fairly limited. On one end of the spec-
trum are patients who were thought to have stage I or II
disease after extensive preoperative staging involving imag-
ing and invasive procedures, but are found postoperatively to
have pN2 disease. The term incidental N2 has been used for
such patients when the nodal involvement is discovered
postoperatively, and perhaps “unsuspected N2” would be
appropriate when it is found intraoperatively in such well-
staged patients. On the other end of the spectrum are patients
with suspicious mediastinal nodes (by computed tomography
[CT] or positron emission tomography) who nevertheless
undergo a resection (without further staging investigations),
which then demonstrates pN2 involvement. These patients
should perhaps be more appropriately called “ignored N2.” In
between these groups are patients with more subtle suspicion
of N2,3 involvement such as those with a central tumor or
with N1 node enlargement, who do not undergo an invasive
staging procedure (even though there is a well-documented
20% chance of N2 involvement despite a normal CT or
positron emission tomography of the mediastinum).19,20 Such
patients who are found to have pN2 disease at the time of
resection should perhaps be called “underappreciated N2.”
These distinctions are important, because pN2 patients with
minimal preoperative investigations cannot necessarily be
expected to have the same survival as those undergoing
extensive preoperative staging. Omitting pursuit of a biopsy
is not the same as a negative preoperative biopsy result.
In assessing long-term outcomes one must be careful to
avoid being misled by studies that report only the survival of
the best subgroup, selected after the fact (i.e., excluding
incompletely resected patients or perioperative deaths). It is
best to consider the outcome for all patients who were
subjected to surgery, because only these data are clinically
applicable to new patients who are being considered for
surgery or are undergoing surgery and are found to have
“surprise” N2 disease. Whether a microscopically complete
resection will be achieved cannot really be determined until
after the resection has been completed. Among patients with
cN2 disease by CT (and pN2 involvement), approximately
one-third will undergo incomplete resection, whereas among
those with cN0,1 disease (and pN2 involvement), approxi-
mately one-fourth are incompletely resected. The vast major-
ity of studies have found extremely poor 5-year survival in
incompletely resected studies (average 4%).21–36
Long-term survival according to how preoperative stag-
ing was done is summarized in Table 1. Only a few studies
have reported outcomes in patients in whom N2 involvement
was proven preoperatively. Although these studies involved
very highly selected patients (generally thought to have only
microscopic disease in a single-node station), 5-year survival for
all patients is only 10 to 15%. This demonstrates that we have
poor ability to select a favorable cohort among patients with
preoperatively proven N2 disease. In other words, if N2 disease
is documented preoperatively, resection does not seem to be
justified because the long-term outcomes are so poor (even
among highly selected patients). The results of alternative treat-
ment approaches (i.e., neoadjuvant therapy and resection or
definitive chemoradiotherapy) for patients with stage III non-
small cell lung cancer (NSCLC) is generally 15%, even
though these approaches have usually involved a broader group
of patients with a larger disease burden in the mediastinum (see
Alternative Treatments section).
In patients with cN2 disease by CT in whom minimal
surgical staging was done, survival after resection is similarly
poor (15%) when pN2 involvement is found. Although the
outcomes seem to be a few percentage points higher than for
preoperatively proven N2 disease, this is likely because of the
inclusion of many studies from Asia (Asian studies generally
seem to have better outcomes, see below). The argument to
forego invasive staging in cN2 patients because of good
long-term outcomes after resection does not seem justified.
The outcomes show that our ability to select favorable pa-
tients among those with suspected N2 disease is disappoint-
ingly poor, and suggests that it is not justified to subject
patients with cN2 disease (“ignored N2”) to thoracotomy
(except perhaps after preoperative chemotherapy in a multi-
modality treatment plan). One could draw the conclusion that
such cN2 patients should be closed and receive chemotherapy
and radiation (with or without subsequent reoperation and
resection). However, the real conclusion has to be that the N2
involvement in these patients should be identified by other
means instead of a thoracotomy.
Careful preoperative staging therefore seems to be impor-
tant, because outcomes of patients with cN2 disease (either
biopsy proven or radiographically suspected) are poor. It is
disturbing, however, that the 5-year survival was very poor
(5–10%) in reported series of patients with cN2 disease (by CT)
in whom the majority underwent a negative mediastinoscopy
(but were nevertheless pN2 after resection).29,37 Therefore a
false-negative mediastinoscopy does not predict a better out-
come. Perhaps these are patients in whom resection should be
aborted in favor of an alternative approach (chemoradiotherapy
or neoadjuvant therapy and later resection). The quality of how
well mediastinoscopy is performed is probably important. A
large series from United States found that not even a single
lymph node was biopsied in approximately half of all medias-
tinoscopies for staging of lung cancer.38 At the other end of the
spectrum is a complete bilateral transcervical extended lymph-
adenectomy for staging (average of 39 nodes removed, missed
mediastinal nodes in only 13%, and a negative predictive value
for N2 disease of 96%).39
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Survival is more acceptable in patients with pN2 dis-
ease that are cN0,1 by CT. In series where limited confirma-
tion of the mediastinal nodes was done, the 5-year survival
for all patients is approximately 27%. Similarly, in series in
which all patients had a negative mediastinoscopy (and cN0-2
disease by CT) the 5-year survival is 26%. Series involving
less rigorously selected patients (cN0-2 by CT and “selec-
tive” [negative] mediastinoscopy) have reported somewhat
inferior survival (22% for all patients, 19% for R0 pa-
tients).26,28,30,40–42 These outcomes suggest that resection of
fairly rigorously staged patients with cN0,1 disease is
justified even if pN2 involvement is found (“incidental
N2”). The survival of patients who have more selective
staging and are found to be pN2 is slightly inferior.







Result R1,2 (%) 5-yr R0
Survival
All Adj Ther Continent
Pearson et al.23 79 ? All Pos 40 15 9 RT NA
Coughlin et al.22 36 ? All Pos 22 18 14a ? NA
Vansteenkiste et al.27 19 ? All Pos 36 ? 15 RT Eu
Average 33 17 13
Régnard et al.25 254 cN2b Noc — 25 23 18 RT Eu
Ichinose et al.46 164 cN2 Few — Excl 27 — None Asia
Watanabe et al.32 106 cN2 No — 50 20 16 None Asia
Tanaka et al.34 84 cN2 Few — 23d — 27 RT  Ch Asia
Suzuki et al.24 87 cN2 Nod —c 36 — 7 Few Asia
Cybulsky et al.55 63 cN2 13d —c 41d — 7 RT  Ch NA
Inoue et al.91e 60 cN2 Sel  Excl 12 — Ch  RT Asia
Tanaka et al.96 45 cN2 Few — Excl 26 — RT  Ch Asia
Martini et al.45f 33 cN2g No — Excl (8)f,h — RT NA
Average (subtotal)i 35 22 15
Andre et al.29 354 cN0,1j Few — 16 31a 29 RT Eu
Ichinose et al.46 242 cN0,1 Few — Excl 34a — None Asia
Suzuki et al.24 135 cN0,1 Nod —c 18 — 43 sFew Asia
Martini et al.45f 118 cN0,1g No — Excl (33)f,h — RT NA
Goldstraw41 86 cN0,1 No — 15d — 27 None Eu
Tanaka et al.34 71 cN0,1 Few — 23d — 30 RT  Ch Asia
Cybulsky et al.55 61 cN0,1 13d —c 41d — 14 RTCh NA
Tanaka et al.96 54 cN0,1 Few — Excl 42 — RT  Ch Asia
Watanabe et al.32 47 cN0,1 No — 34 33 17 None Asia
Daly et al.98 33 cN0,1 Few —c 15 31 28 RT NA
Sakao et al.99 30 cN0 Few — Excl 52 — None Asia
Averagei 23 37 27
Vansteenkiste et al.27 68 cN0,2 100 Neg 15 — 32 RT Eu
Goldstraw et al.41 62 cN0,2 100 Neg 15d — 23 None Eu
Pearson et al.23 62 cN0,2 100 Neg 35 41 24 RT NA
Average 22 41 26
Inclusion criteria: studies reporting on 30 operated pN2 patients in whom preoperative characteristics are well defined by CT, mediastinoscopy, or both (15 patients for the
category of positive mediastinoscopy); published from January 1980 to June 2007.
a Estimated from data provided.
b In the vast majority.
c 5% Mediastinoscopy-positive patients included.
d Proportion for all patients in study, not necessarily for each subgroup.
e Excluded operative mortality (2%).
f Lung cancer-specific survival.
g As defined by chest radiograph (not CT).
h 4-yr survival.
i Excluding values in parentheses.
j All patients were either radiographically N0,1 or had negative mediastinoscopy.
Adj. ther., adjuvant therapy; c, clinical staging; Ch, chemotherapy; Eu, Europe; excl, excluded from study; NA, North America; p, pathologic; R0, complete resection (negative
margin); RT, radiotherapy; Select pts, mediastinoscopy performed in at least all patients with radiographic N2 disease (in most series also in patients with T3 tumors and central
tumors); ?, unknown;  both negative and positive.
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Patients with “underappreciated N2” disease probably fall
within this group. The survival of this group indicates that
resection is reasonable, although it also suggests that more
diligent preoperative staging may be worthwhile.
Across all studies the 5-year survival in series from
North America seems to be approximately half that of
European of Asian series (7 versus 18 versus 17% for cN2;
14 versus 28 versus 30% for cN0,1 with limited preoper-
ative invasive staging, respectively). This is important to
keep in mind, as there are regional differences in lung
cancer on different continents (high proportion of squa-
mous cancers in Europe, higher proportion of adenocarci-
noma, bronchioloalveolar carcinoma, and endothelial
growth factor receptor abnormalities in Asia). There also
seem to be cultural differences in how specific lymph
nodes are classified, and a node near the pleural reflection
is more likely to be classified as N2 by Japanese surgeons
and N1 by European surgeons.43 It is unclear how this
compares with classification practices in North America. A
revised node map that seeks to reconcile continental dif-
ferences is being developed.44
Specific Situations
It is difficult to define how a specific factor should
influence the intraoperative decision of whether to proceed
with resection, because one factor can really not be viewed in
isolation from others. The importance of the extent of preop-
erative staging has already been discussed. Furthermore,
there are geographic variations in outcomes. Finally, it is
unclear how well postoperative criteria that define subgroups
with good or poor survival can be extrapolated to factors that
can de determined intraoperatively. Each of these issues
confounds the ability to define prognosis relative to a single
factor accurately enough to dictate how such a patient should
be managed when surprise N2 is found.
Several studies have performed multivariate analyses
of multiple factors, which is the necessary approach when there
are multiple interrelated factors (Table 2). These studies indicate
that an incomplete resection, multilevel N2 involvement, clinical
N2 stage (by CT), and subcarinal node involvement are inde-
pendent markers of poor prognosis in more than half of the
studies. The presence of T3,4 tumors, pN1 disease, and increas-
ing age are less consistent negative prognostic markers of a
worse prognosis. The histologic type of NSCLC, or whether the
tumor involves a lower or upper lobe does not seem to be
important. Similarly whether a pneumonectomy or lobectomy is
needed has little independent prognostic significance.
The clinically relevant issue is whether any intraop-
erative findings preclude proceeding with a resection be-
cause the outcome is likely to be very poor. An analysis of
all larger series reporting survival data on particular pa-
tient subgroups is shown in Tables 3 and 4. The inclusion
criterion for this review was chosen so that there would be
sufficient numbers of patients in each group to have
reasonably reliable survival estimates. Furthermore, it was
chosen to focus on studies reporting on a variety of factors
(as opposed to smaller studies that focused on a specific
factor) in an effort to reduce publication bias. However,
this review is compared with another systematic review
involving any study reporting on 20 patients in a partic-
ular subgroup.40
The available data suggests that resection is not
justified if it is incomplete. The long-term survival is
TABLE 2. Multivariate Analyses of Factors Predicting Poor Survival in pN2 Patientsa











Andre et al.29 702 0.0001 0.0001 NS — — — — 0.0001 — — — NS —
Ichinose et al.46 406 0.0001 NS — 0.03 — — — 0.05b — — NS NS 0.02
Riquet et al.31 237 0.05 — 0.05 NS NS NS NS NS NS NS NS NS —
Suzuki et al.24 222 0.001 <0.001 0.02 — — — — NS 0.001 — NS NS NS
Miller et al.28 167 0.05 — NS — 0.05 NS (NS)c NS — — 0.05 NS 0.05
Thomas et al.33 163 0.02 — — — NS — NS NS — — — NS —
Tanaka et al.34 155 NS NS 0.001 — — — — 0.03 — — — NS NS
Inoue et al.91 154 0.005 <0.001 — — — — — NS — 0.04 — 0.002 0.007
Iwasaki et al.93 142 NS — — NS 0.002 — — NS — — NS NS NS
Vansteenkiste et al.27 140 0.03 0.04 NS — NS NS (NS)c 0.003 — NS NS 0.03 NS
Tanaka et al.96 99 0.01 <0.04 — — — — — NS — — — NS NS
Ohta et al.97 94 — NS — 0.03 <0.001 — NS <0.001 NS NS — NS NS
Prognostic valued High Mod Mod Mod Mod — — Low Low Low — — Low
Inclusion criteria: studies reporting multivariate analysis of 90 patients with pN2 disease, 1980–2007.
a Values given are p values by multivariate analysis (plain: relative risk 1.0–2.0; The values given in bold are relative risk 2.0–3.0; The values given in bold-underlined
are relative risk 3.0). Factors analyzed by less than three studies are omitted.
b T2,3 vs. T1.
c Stations 1–4 vs. others.
d Scale, high: 75% positive; moderate: 50–74% positive; low: 25–49% positive (excluding values in parentheses).
Adeno/large, adenocarcinoma, in some cases also including large cell carcinoma (not squamous); cN2, clinical N2 by CT; mod, moderate; N1, N1 nodes involved (nonskip
metastasis to N2 nodes); NS, not statistically significant; pneum, pneumonectomy; R1,2, incomplete resection; T3,4, T3, or T4 primary tumor.
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consistently poor (average 5%, range 0–10%). This is true
in this review and in others (involving different inclusion
criteria).40 The definition of an incomplete resection var-
ies, being defined by some as a microscopically positive
margin,27–31,35,41,45,46 whereas others also include patients
with extracapsular involvement of a mediastinal node,47
and others include patients in whom the most distant
(highest) node was positive.24,33,34,48 However, the survival
of incompletely resected patients seems to be consistently
poor, regardless of the definition. Extracapsular extension
TABLE 3. Survival of pN2 Patients with Particular Negative Prognostic Factors
Study n
5-Yr Survival (%)
R1,2 cN2 Multi T3 Pneum 7 1,2 Ad/Lg LL N1
Survival of all operated patients (R0-2 resections)
Andre et al.29 702 10 7 7 13a — — — 13 — —
Naruke et al.21 545 8b — — 14 — — — 21 — —
Maggi et al.30 278 0 — 15 10 — 8 — — — —
Régnard et al.25 254 0c 18 9 11 — 18d — — — —
Riquet et al.31 237 8 — 8 — — — — — — —
Suzuki et al.24 222 0e 7 19 13a 13 — — 31 — —
Wada48 214 —e — — 15 — — — — — —
Watanabe et al.32 199 0 — 9 — — 23d — — — —
Miller et al.28 167 5 — — — 18 13 3 — — —
Thomas et al.33 163 —e — — — — 14 8 — — —
Tanaka et al.34 155 6e 25 25 15 — — — 27 — —
Watanabe et al.35 153 0 16 7 15 — — — 24 — —
Goldstraw et al.41 149 — — — — 21 27 — 4 — —
Vansteenkiste et al.27 140 4 15 22 2 22 14 — 18 20 —
Cybulsky et al.55 124 —c 7 — — — — — — — —
Ishida et al.36 115 9b 16 — 0 — — — 19 — —
Average (all patients) 4 14 13 11 19 17 (6)f 20 (20)f —
Survival limited to R0 resected patients
Ichinose et al.46 402 — 27 17 30 17 — 28 23g 26
Mountain101h 307 — — (21)h,i (29)h — — (25)h (26)h — —
Régnard et al.25 191 — 23 — — — — — — — —
Maggi et al.90 157 — — 18 14j — 9d — — — —
Inoue et al.91k 154 — — 16 — — — — 24 21 —
Rea et al.92 154 — — 0 — — — — — — —
Martini et al.45h 151 — (8)h,l (27)h (22)h — (25)h — (36)h — —
Iwasaki et al.93k 142 — — 10 — — 0d — — — —
Okada et al.94 141 — — 11 — 26 — — — — —
Conill et al.95 113 — — 3 — — 16 — — — —
Tanaka et al.34 94 — — — 28 — — — 32 — —
Ohta et al.97 94 — — — — — — — — — 20
De Leyn et al.42 90 — — 25 0 — — — 20 — —
Average (R0 patients)m — (25)f 13 18 (22)f (8)f — 26 (22)f (23)f
Inclusion criteria: studies of 90 pN2 patients reporting survival by prognostic factor.
a T3 and T4.
b Defined as positive margin (R1,2) or no complete node dissection performed.
c No definition provided.
d Single level involvement.
e Defined as positive margin (R1,2) or highest node positive.
f Data from less than three studies.
g Data reported in Ichinose 2001.100
h Cancer-specific survival (death from unrelated causes excluded).
i Estimated from reported data.
j Reprinted with permission from Maggi G. Results of radical treatment of stage IIIa non-small-cell carcinoma of the lung. Eur J Cardiothorac Surg 1988;2:329–335.
k Excluded operative mortality.
l 4-Yr survival.
m Excluding values in parentheses.
7, Nodal station 7; 1,2, nodal station 1,2; Ad/Lg, adenocarcinoma, in some cases also including large cell carcinoma (not squamous); cN2, clinical N2 by CT; LL, lower lobe;
multi, multilevel node involvement; N1, N1 nodes involved (nonskip metastasis to N2 nodes); pneum, pneumonectomy; R1,2, incomplete resection, defined as microscopic or gross
residual except as indicated; T3, T3 primary tumor.
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was not of prognostic significance in multivariate analy-
ses,27,31 and neither was involvement of the highest lymph
node (Table 2). The only study to investigate some aspects
of the definition of incomplete resection concluded that
only a mere lack of a complete lymph node dissection did
not confer a poor outcome and should not be used as a
definition of incomplete resection (as opposed to a positive
margin or the most distant node being positive).7 There-
fore, it seems reasonable to conclude that there is little
justification for proceeding with a resection if it can be
determined that it will be incomplete, with the most robust
definition being a positive margin.
Several factors listed in Table 3 can be grouped as
relatively negative prognostic factors, namely clinical N2
by CT, multilevel N2, T3 tumors, or subcarinal node
involvement (5-year survival of 14, 13, 11, and 17%
respectively, as shown graphically in Figure 1A). These
data are in close agreement with a previous systematic
review (5-year survival rates of 15, 13, and 15% for
multilevel N2, T3 tumors, or subcarinal node involvement,
respectively).40 However, the range of reported results
varies quite widely from values that would quite clearly
argue against proceeding with resection (5% 5-year
survival), to values that would argue for resection (20%
5-year survival). This is likely because of the confounding
factors. For example, the subcarinal node results are likely
confounded by inclusion of patients with multilevel or
nonregional node involvement, because more lung cancers
TABLE 4. Survival of pN2 Patients with Particular Positive Prognostic Factors
Study n
5-Yr Survival (%)
R0 cN0,1 Single T1,2 Lobe Sq UL N1- 5
Survival of all operated patients (R0-2 resections)
Andre et al.29 702 23 29 25 22 — 20 — — —
Naruke et al.21 545 23 — — 21a — 31 — — —
Maggi et al.30 278 18 — 22 20 — — — — —
Régnard et al.25 254 23 — 24 29a — — — — —
Riquet et al.31 237 20 — 26 — — — — — —
Suzuki et al.24 222 36 43 35 31 31 21 — — —
Wada et al.48 214 — — — 34 — — — — —
Watanabe et al.32 199 20 — 35 — — — — — —
Miller et al.28 167 24 — — — 31 — — — 24
Tanaka et al.34 155 34 30 37 33a — 27 — — —
Watanabe et al.35 153 24 33 35 33 — 22 — — —
Goldstraw et al.41 149 20 — 21 14 21 30 — — —
Vansteenkiste et al.27 140 25 22 20 29a 14 22 24 — 20
Cybulsky et al.55 124 — 14 — — — — — — —
Ishida et al.36 115 26 24a — 23a — 15 — — —
Average (all) 24 28 28 26 24 24 (24)b — (22)b
Survival limited to R0 resected patients
Ichinose et al.46 402 31 34a 43 31a 33 37 37c 46 —
Maggi90 157 23 — 25 22d — — — — —
Inoue et al.91e 154 28 — 43 — — 40 35 — —
Rea et al.92 154 13 — 18 — — — — — —
Iwasaki et al.93e 142 24 — 37 — — — — —
Okada et al.94 141 26 — 39 — 26 — — — —
Conill et al.95 113 10 — 16 — — — — — 0
Tanaka et al.34 94 35 42 42 43 — 44 — — —
Ohta et al.97 94 27 — — — — — — 33 —
De Leyn et al.42 90 22 — 24 34 — 26 — — —
Average (R0) 24 (38)b 32 33 (30)b 37 (36)b (40)b (0)b
Inclusion criteria: studies of 90 pN2 patients reporting survival by prognostic factor.
a Estimated from reported data.
b Data from less than three studies.
c Data reported in Ichinose 2001.100
d Data reported in Maggi 1988.54
e Excluded operative mortality.
5, Nodal station 5; Ad/Lg, adenocarcinoma, in some cases also including large cell carcinoma (not squamous); cN0,1, clinical N0 or N1 by CT; lobe, lobectomy; N1-, N1 nodes
not involved (skip metastasis to N2 nodes); R0, complete resection, defined as negative margins; single, single-level node involvement; Sq, squamous cell cancer; T1,2, T1, or T2
primary tumor; UL, upper lobe.
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originate in the upper lobes, which predominately spread
to paratracheal nodes. The large International Association
for the Study of Lung Cancer (IASLC) staging revision
database confirmed worse survival for multilevel pN2
involvement with a 5-year survival of 20% (other factors
such as T stage were not able to be analyzed).49
Several factors stand out as relatively consistent posi-
tive prognostic factors (Figure 1B). These include a R0
resection, a T1,2 tumor, single-level N2 involvement, and
patients staged as clinical N0,1. Although the reported sur-
vival ranges are broad (Table 4), they do quite consistently
support resection for surprise N2 discovered at thoracotomy.
These results are consistent with that of other reviews.40,49,50
Factors that seem to have limited value in differentiat-
ing patients with good or poor prognosis include the histol-
ogy, extent of resection, and in more limited data the location
of the tumor (upper versus lower lobe), and the presence of
involved N1 nodes (5-year survivals of 20% for adenocarci-
noma, 26% for squamous cancer, 19% for pneumonectomy,
24% for lobectomy, 20% for lower lobe, 24% for upper lobe
[among operated patients], and 23 versus 40% for nonskip
and skip N2 [among completely resected patients]). These
results are all consistent with another systematic review,40
and the IASLC staging project did not define a consistent
difference with respect to skip N2 involvement.49 A limited
amount of data in the analysis presented here suggests that
survival is poor (6%) if there is involvement of the highest
mediastinal nodes (stations 1 and 2). However, another sys-
tematic review found an average 5-year survival of 18% in
such patients (involving three studies of 20 such patients,
primarily completely resected).40 Finally, multivariate analy-
ses have not found this factor to be important.
Tumors in the left upper lobe (LUL) with involvement
of aortopulmonary window (APW) lymph nodes deserve
specific mention. A number of authors have reported partic-
ularly good results (40% 5-year survival) in these patients,
but have done so by reporting on only selected patients (only
completely resected, often with other node stations nega-
tive).51–53 Results applicable prospectively to patients as they
are encountered in the clinic or operating room demonstrate
approximately 20 to 30% 5-year survival for patients with
station 5 nodal involvement.40 These results are not clearly
different than those of tumors in other lobes involving only a
single mediastinal node station. Furthermore, multivariate
analysis has not demonstrated that APW nodes carry any
particular significance. A previous review of studies involving
20 patients found similar survival among pN2 patients with or
without APW node involvement, with conflicting trends and no
statistically significant difference in any of the studies
analyzing this.40 The IASLC staging revision project found
no difference in survival for single-level pN2 involvement
of subcarinal versus APW nodes for left-sided lung can-
cers.49 Therefore, although the data suggests that LUL resec-
tion should proceed if APW node involvement is found, the
preponderance of data does not support that the LUL and the
APW represent a biologically different situation than other
lobes and regional nodal areas.
FIGURE 1. A, Negative prognostic factors for patients
with pN2 NSCLC. Inclusion criteria: studies of 90 pN2
patients reporting survival by prognostic factor. cN2, clini-
cal N2 by CT; level 7, nodal station 7; multi, multilevel
node involvement; pts, patients; R0, complete resection;
R1,2, incomplete resection; T3, T3 primary tumor.
R1,221,24,25,27–32,34–36; multi, all patients24,25,27,29–32,34,35; R0
resections42,46,90–95; T3, all patients21,24,25,27,29,30,34–36,48; R0
resections42,46,54,96; cN2, all patients24,25,27,29,34–36,55; R0 resec-
tions25,46; station 7, all patients25,27,28,30,32,33,41; R0 resec-
tions.90,93,95
B, Positive prognostic factors for patients with pN2
NSCLC. Inclusion criteria: studies of 90 pN2 patients report-
ing survival by prognostic factor. cN0,1, clinical N0 or N1 by
CT; level 7, nodal station 7; pts, patients; R0, complete resec-
tion; single, single-level node involvement; T1,2, T1 or T2 pri-
mary tumor. References R021,24,25,27–32,34–36,41,42,46,90–97; T1,2,
all patients21,24,25,27,29,30,34–36,41,48; R0 resections42,46,54,96;
single, all patients24,25,27,29–32,34,35,41; R0 resections42,46,90–96;
cN0,1, all patients24,27,29,34–36,55; R0 resection.46,96
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A few studies have investigated the prognostic value of
involvement of only “regional” N2 nodes,24,27,32,53 with con-
flicting and unclear results. Okada et al. suggested that
survival is dramatically better for patients with upper lobe
tumors involving only stations 1 to 6 versus 7 to 9, for lower
lobe tumors involving stations 7 to 9 versus 1 to 4, and to a
lesser extent left upper lobe tumors involving stations 5 and
6 versus any others.53 Another study has qualitatively re-
ported very poor outcomes with involvement of nonregional
nodes.27 However, a third study found no survival difference
in patients with upper lobe tumors involving stations 1 to 4
versus 7 to 9, and found significantly worse survival with
lower lobe tumors involving stations 7 to 9 versus 1 to 4.24
Finally, Watanabe et al. found no difference in 144 com-
pletely resected patients.32
What conclusions can be drawn? First, application of
the data regarding a specific factor should be done with
caution, because of confounding variables such as the extent
of preoperative staging, clinical node status, geographic vari-
ation, and other factors. Second, it seems fairly clear that
there is little point in proceeding with a resection that is
expected to be incomplete. Third, if it seems likely that a
complete resection can be accomplished it is generally ap-
propriate to proceed, given that the morbidity and mortality
of the thoracotomy and its effect on the feasibility of deliv-
ering chemoradiotherapy in a timely fashion has already been
incurred. This is fairly clearly true in the case of a T1,2 tumor,
single-level node involvement, and patients with a cN0,1 tumor
based on careful preoperative staging. This is probably also true
for patients with upper lobe tumors involving only regional
nodes (LUL and station 5 or right upper lobe and R4). One
should not hesitate to carry out a pneumonectomy if necessary
(provided the patient is able to tolerate this), and should not
change the approach based on the histologic subtype. The
situation is less clear in patients with multilevel N2, clinical N2
by CT, T3 tumors, or subcarinal node involvement. However,
although these patients seem to have worse survival (around
15%), in general resection is justified unless there are significant
comorbidities or multiple poor prognostic factors.
HOW MUCH RESECTION IS NEEDED?
Lobectomy versus Pneumonectomy
Controversy exists about whether a lobectomy or pneu-
monectomy should be performed if N2 disease is encoun-
tered. Some surgeons believe that a pneumonectomy should
always be performed if N2 disease is encountered, to more
completely remove tumor-bearing lymphatics. Unfortunately,
this issue has not clearly been addressed by any study. Most
studies have shown worse survival after pneumonectomy
than lobectomy,26,28,37,54,55 although some found the oppo-
site.27,41 This is almost certainly confounded by more exten-
sive tumors (higher T stage) in patients requiring pneumo-
nectomy.37,54 Nevertheless, these data undermine the
argument that there is something to be gained from a pneu-
monectomy, and the data in Table 3 suggest that survival is
reasonable even if pneumonectomy is required. Furthermore,
the meta-analyses in Table 2 do not demonstrate the extent of
resection to be of prognostic significance. Finally, although
the lymph nodes in stations R4, 7, and 5 are adjacent to the
mainstem bronchi, it is not clear how pneumonectomy and
MLND actually result in a more complete resection of in-
volved N2 nodes compared with a lobectomy and MLND.
Occasionally, a central tumor is amenable to a sleeve
resection (involving the bronchus, pulmonary artery, or both)
as an alternative to a pneumonectomy. An average 5-year
survival of 27% has been found among studies reporting
specifically on patients with pN2 disease undergoing sleeve
resection.56–62 This does not seem to be noticeably different
than the survival of pN2 patients undergoing a standard
lobectomy, and is not worse than the survival of pN2 patients
undergoing pneumonectomy (Tables 3 and 4). Therefore, the
data support sleeve resection as a reasonable alternative to
pneumonectomy even in the face of N2 disease.
THE VALUE OF MLND
Role of MLND in Staging
Intraoperative handling of the mediastinum can involve
a complete MLND, a systematic node sampling, or a selective
sampling. A formal MLND involves removal of all of the
node-bearing tissues, leaving only the skeletonized trachea,
phrenic nerves, aorta, and superior vena cava behind.35 A
systematic mediastinal node sampling means that the pleura
overlying each ipsilateral node station is opened, explored,
and representative biopsies of nodes are obtained. A selective
sampling, on the other hand, involves biopsy of only selected
mediastinal nodes that are felt to be abnormal. Some authors
advocate a lobe-specific systematic node dissection, which
consists of a complete dissection of those nodal regions most
often involved by tumors in a particular lobe.63
It is well established that a complete MLND can be
carried out safely with only a minor impact on operative
times or morbidity (Table 5).10,64–68 The standard of care for
surgical management of lung cancer in general is to perform
either a systematic lymph node sampling, a complete MLND,
or a lobe-specific MLND.63,69,70 The issue to be considered
here is whether a particular approach can be recommended
when surprise N2 disease is encountered.
The accuracy of staging seems to be improved by
diligent intraoperative attention to mediastinal staging. Sev-
eral controlled and randomized studies have shown that
systematic sampling approximately doubles the rate of dis-
covery of N2 node involvement relative to a selective medi-
astinal node sampling.10,64,68 However, a systematic node
sampling detects essentially the same number of patients with
pN2 node involvement as a complete MLND.65,67,71 A
MLND may detect more patients with multilevel N2 involve-
ment than systematic sampling,65,71 even though the stage
classification is the same (59% versus 17%, p  0.01 in one
study of cI–IIIa patients,71 but no difference in another
involving cIa patients67). This staging data suggest that less
extensive node removal at thoracotomy might leave tumor
behind in some instances.
THERAPEUTIC ROLE OF MLND
The therapeutic role of MLND is unclear at this time.
Four randomized trials have been conducted (Table 6),10,66–68
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but survival data are not available yet from the largest one
(American College of Surgeons Oncology Group Z0030).10 A
smaller study of stage cIa patients found no survival differ-
ence, but is probably less applicable to the topic of this
review.67 The other two trials are somewhat suggestive of a
benefit either in overall survival or in local control.66,68 A
systematic review of these trials carried out by the Cochrane
collaboration found better 4-year survival with MLND versus
node sampling (hazard ratio 0.78, p  0.005).72 A retrospec-
tive review of data from a large trial of adjuvant therapy (355
patients, pII–IIIa) suggested a survival benefit with MLND,73
but another retrospective study (125 patients, pIa) suggested
worse survival.74
An extended mediastinal node dissection involving
bilateral mediastinal node dissection by means of a sternot-
omy has been advocated by some to more completely
remove all nodal disease.52 In a study of 44 patients with
cI–IIIa LUL tumors, 32% were found to be pN2, of which
half had involvement of stations 1, 2R, 4R, 2L. However,
although survival was good for those patients with pN2
limited to the usual nodal regions assessed during LUL
resection (stations 4L. 5–7), none of the patients with
involvement of nodes in the extended field of resection
survived 5 years. The patients in this study were treated with
surgery alone in the vast majority (no neoadjuvant or adju-
vant chemo- or radiotherapy).52 Thus there seems to be little
benefit to such extended node dissection, at least in the
absence of additional treatment modalities.
Therefore the available data does not clearly define
whether there is a therapeutic benefit to MLND. However, it
seems reasonable to recommend that in general a MLND be
done if intraoperative N2 disease is found. This recommen-
dation is based on the trend to better survival and decreased
local recurrence in the randomized studies. Furthermore, the
randomized studies involved a broader group of patients of
which only a minority had pN2 disease. If intraoperative N2
disease is found, it seems prudent to try to remove the
ipsilateral nodal areas as completely as possible.
POSTOPERATIVE (ADJUVANT) THERAPY
A full discussion of the role of adjuvant therapy for
pN2 patients is beyond the scope of this article. In general,
adjuvant chemotherapy has become standard for resected
stage II–IIIa NSCLC patients. Specific evidence-based rec-
ommendations for resected stage pIIIa patients are addressed
by the recently revised ACCP guidelines.69 These guidelines
recommend postoperative chemotherapy, and suggest that
consideration be given to subsequent postoperative radiother-
apy (RT) as well. Concurrent adjuvant chemoradiotherapy is
not recommended.69
A stage-specific meta-analysis of adjuvant chemother-
apy for patients with stage IIIa disease published in 2005
found a hazard ratio strongly in favor of chemotherapy of
0.85 (95% confidence interval 0.69–1.04).75 This did not
quite meet criteria for statistical significance. It is probably
significant that this meta-analysis did not include the more
recently reported results of the Adjuvant Navelbine Interna-
tional Trialist Association trial, which were strongly positive
in favor of adjuvant chemotherapy.76 Taken in the broader






Addit’l OR Time Oper Mort Surg Morb pN2 (%) ML of N2 (%)
(min) p LND Sampl p LND Sampl p LND Sampl p LND Sampl p
Allen et al.10 1023 cN0,1 Select 15 0.0001 2 1 NS 38 38 NS 4a 0a — — — —
Wu et al.68 471 cI-IIIa Select — — 0.3 0 NS — — — 48 28 — — — —
Izbicki et al.71 182 cI-IIIa Syst — — — — — — — — 27 23 NS 59 17 0.007
Sugi et al.67 115 cT1N0 Syst 42 0.05 0 0 NS 27 3 0.05 12 14 NS 43 38 NS
Inclusion criteria: randomized studies of lymph node dissection vs. a method of lymph node sampling in patients with NSCLC undergoing surgical resection.
a Any patients with N2 involvement identified intraoperatively were excluded.
Addit’l OR time, additional operative time for LND in minutes; elig crit, eligibility criteria; min, minutes; LND, lymph node dissection; ML, percent of patients with multilevel
N2 involvement among those with N2 involvement; NS, not statistically significant; oper mort, operative mortality (in hospital or within 30 d); p, p value; sampl, node sampling;
select, selective sampling (only abnormal appearing nodes); surg morb, surgical morbidity (complications); syst, systematic sampling (exploration of each ipsilateral node station with
representative biopsy).
TABLE 6. Mediastinal Lymph Node Dissection: Survival and Recurrence Data from Randomized Studies
Study n Elig Crit Sampl Method
5-Yr Survival (%) Local Recurrence (%)
LND Sampl p LND Sampl p
Allen et al.10 1023 cN0,1 Select — — — — — —
Wu et al.68 471 cI-IIIa Select 48 37 0.0001 3 5 —
Izbicki et al.66 182 cI-IIIa Syst (71)a (60)a NS 41 79 0.04
Sugi et al.67 115 cT1N0 Syst 81 84 NS — — —
Inclusion criteria: randomized studies of lymph node dissection vs. a method of lymph node sampling in patients with NSCLC undergoing surgical resection.
a 3-yr survival.
Elig crit, eligibility criteria; LND, lymph node dissection; NS, not statistically significant; p, p value; sampl, node sampling; select, selective sampling (only abnormal appearing
nodes); syst, systematic sampling (exploration of each ipsilateral node station with representative biopsy).
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context of adjuvant therapy studies including such more
recent results there is little doubt that adjuvant chemotherapy
is beneficial. This is reflected in the guideline statements
mentioned above.
The role of adjuvant RT for patients with stage IIIa
disease is not clear. Systematic reviews of adjuvant RT for
completely resected (R0) stage pI–IIIa NSCLC have gener-
ally found that there is a detriment to survival, although local
control seems to be improved.77–79 The survival detriment
was manifest primarily in patients with stages I and II
NSCLC. The available data did not allow a specific recom-
mendation for patients with stage IIIa tumors in these re-
views. A retrospective review in 2006 of Surveillance, Epi-
demiology and End Results (SEER) data in 7465 patients
suggested that patients with pN2 disease have a survival
benefit with adjuvant RT.80 It was suggested that modern RT
techniques may have decreased the toxicity of treatment to
the point where a survival benefit in stage III was realized.
This leaves it unclear whether RT should be used in com-
pletely resected patients with pIIIa tumors.
Adjuvant RT is generally given to incompletely re-
sected (R1) patients. The argument for this is that the trend to
better local control with adjuvant RT justifies its use in
patients suspected to be at high risk for local failure such as
those with an incomplete resection. However, there is little
data to substantiate (or refute) this argument.78 Nevertheless,
this seems to be a rational approach, and should probably be
followed sequentially by chemotherapy. In the case of gross
residual disease (R2), it seems best to treat the patient as if they
had undergone a large biopsy rather than a resection. These
patients should be managed with concurrent chemoradiotherapy
once they have sufficiently recovered from surgery (although
direct data to substantiate this strategy is not available).
Does the delivery of adjuvant therapy affect the intra-
operative management when N2 disease is discovered? There
is no data that directly examines this. One must keep in mind
that the ability to deliver adjuvant therapy postoperatively has
consistently been relatively poor (approximately 65%).69,78,88
Nevertheless, the data reviewed in this article comes from
studies in which many patients did receive adjuvant therapy
(Table 1). Therefore, it would seem that the data presented
and conclusions reached in this review apply to patients in the
current setting, in which adjuvant therapy is generally rec-
ommended for pN2 patients.
ALTERNATIVE TREATMENT APPROACHES
Primary Alternative Treatment Approaches
A full discussion of alternative treatment approaches
other than primary surgery for patients with pN2 disease is
beyond the scope of this article. Nevertheless, a brief sum-
mary is necessary to place the results with primary surgery in
the proper perspective.
The standard of care for stage IIIa NSCLC is concur-
rent chemoradiotherapy.69 The 5-year survival rates in these
studies has been approximately 15 to 20%.81,82 It is important
to note that these trials have included patients with much
more extensive stages IIIa and IIIb disease than the patients
that are the focus of this article. Induction therapy followed
by surgical resection is a reasonable alternative, although at
the present time it should ideally be done in the context of a
clinical trial.69 This has been compared with chemoradiother-
apy alone in a randomized trial, with no statistical difference
in overall survival.83,84 Significantly better progression-free
survival in the surgical arm was offset by an increase in initial
(perioperative) mortality. The 5-year survival seems to be
approximately 25% for such trimodality approaches in pre-
operatively proven cN2 involvement.69,84,85 More aggressive
chemoradiotherapy approaches are also being explored, with
survival rates of 25 to 30% in phase II studies (in a broad
group of stages IIIa and IIIb patients).13,86,87 Although direct
comparisons are not possible because of differences between
the patients included in these studies and patients with “sur-
prise” pN2 disease, these results must be kept in mind when
considering the role of primary resection.
Effect of Exploration on Alternative
Approaches
Should an alternative treatment strategy be considered
when surprise N2 disease is encountered at thoracotomy? The
outcomes of alternative treatment approaches just discussed
pertain to patients that have not been subjected to an explor-
atory thoracotomy. No data are available that specifically
defines the ability to carry out such an alternative approach
after a thoracotomy. However, there are extensive data that
adjuvant chemotherapy can be administered as planned in
only about 65% of patients after a resection.69,78,88 It is
possible that a higher percentage of patients can tolerate and
complete chemotherapy after an exploratory thoracotomy
compared with after a resection, but this is speculative and
not supported by the similar perioperative mortality of explo-
ration and resection. Furthermore, definitive chemoradiother-
apy treatment approaches for stage III NSCLC have involved
more intense treatment than those of adjuvant therapy. This
makes it likely that any better tolerance of alternative treat-
ment that might be realized after an exploratory thoracotomy
compared with resection would probably be offset by worse
tolerance of more intensive therapy than the 65% reported in
adjuvant chemotherapy studies. In summary, speculative ex-
trapolation of existing data suggests that only about two-
thirds of patients are likely to complete definitive chemora-
diotherapy after an exploratory thoracotomy.
The likelihood of completing the planned treatment
seems likely to be worse if the alternative therapy under
consideration is neoadjuvant chemotherapy followed by a
second thoracotomy, this time with resection. The same con-
cerns about the ability to complete the neoadjuvant treatment in
a postoperative patient apply as was discussed in the preceding
paragraph. In addition, studies of neoadjuvant treatment fol-
lowed by resection have consistently found that only about 65%
of patients are well enough to undergo resection after the
induction therapy.81 Thus, only about 50% of patients who are
closed after finding surprise N2 disease at thoracotomy can be
expected to complete neoadjuvant therapy and subsequent sur-
gical resection. It is highly likely that those patients not com-
pleting the planned alternative therapy will experience very poor
survival. Unfortunately, no direct data to confirm or refute these
extrapolative estimates are available.
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SUMMARY: APPROACH TO PATIENTS
What conclusions can be drawn? First, any suspicion of
N2 disease warrants careful and thorough invasive staging,
and documentation of N2 involvement should preclude initial
thoracotomy and resection. Such patients with pN2 disease
who are cN2 by imaging studies have a 10 to 15% survival
rate (despite adjuvant RT). Given the morbidity of surgery,
and the fact that other curative-intent treatment options are
available, surgical resection as the initial treatment does not
seem justified. The nodal involvement should be identified
using a less invasive method than a thoracotomy. It is not
entirely clear whether these patients should be managed by
chemoradiotherapy alone or in some instances by neoadju-
vant treatment followed by resection, although the most
recent guideline recommendation is for chemoradiotherapy
alone outside of a clinical trial.69
Some patients will be found to have N2 involvement at
the time of resection, even if appropriate preoperative staging
has been done (“unsuspected N2”). The only clear reason to
abort the planned operation is if it is apparent that a complete
resection is not possible. Aside from this, it seems in general
to be appropriate to proceed with resection (especially if careful
preoperative staging demonstrated cN0,1 disease). Survival of
some subgroups may be slightly better and of others slightly
worse, but the outcomes are nevertheless good enough to pro-
ceed with resection. This argument is based on data that a 5-year
survival of 10 to 50% can be anticipated and on data that there
is little difference in the operative mortality or QOL whether the
procedure is aborted or carried out. Furthermore, the ability to
give an alternative treatment (definitive chemoradiotherapy or
neoadjuvant therapy followed by resection) is somewhat ques-
tionable in a postoperative patient.
Defining particular factors that might influence the
intraoperative decision to resect should be done very cau-
tiously, because the reported results vary and are likely
confounded by multiple undefined additional factors. Pro-
ceeding with resection is clearly justified in the case of a T1,2
tumor, single-level node involvement, and patients with a
cN0,1 tumor based on careful preoperative staging. This is
probably also true for patients with upper lobe tumors involv-
ing only regional nodes (LUL and station 5, or RUL and R4).
One should not hesitate to carry out a pneumonectomy if
necessary (provided the patient is able to tolerate this), and
should not change the approach based on the histologic
subtype. Worse outcomes (around 15% 5-year survival) are
seen in patients with multilevel N2, clinical N2 by CT, T3,4
tumors, or subcarinal node involvement, but in general resec-
tion is still justified unless there are significant comorbidities
or perhaps multiple poor prognostic factors.
It seems appropriate to proceed with resection even
when faced at the time of thoracotomy with N2 involvement
and an expected 15% 5-year survival (with negative prognos-
tic factors), whereas at the same time it seems appropriate to
avoid surgery altogether for patients with cN2 as defined
preoperatively (because of 10–15% expected survival). This
is because there is much more to be gained from avoidance of
the morbidity of a thoracotomy than from aborting a resection
once the thoracotomy has been done. Furthermore, alternative
treatment is easily available if thoracotomy is avoided, but is
more difficult once it has been done.
This conclusion is in conflict with an earlier study using
mathematical modeling, which concluded that it was always
better to close on finding surprise N2 and to administer
neoadjuvant therapy and then resection.89 However, this
model was based on several assumptions that are not borne
out by current literature: a 2.6-fold improvement in survival
after neoadjuvant therapy and resection versus chemoradio-
therapy alone, a 100% ability to deliver neoadjuvant therapy
after exploratory thoracotomy, no benefit to adjuvant therapy
after resection, and an operative mortality for exploratory
thoracotomy of 0.5%. Countering these assumptions is the
data from the only randomized study, which found no differ-
ence between neoadjuvant therapy and resection versus che-
moradiotherapy alone.83,84 Meta-analyses have demonstrated
a benefit to adjuvant chemotherapy for resected IIIa pa-
tients.69 The ability to deliver chemoradiotherapy seems to be
poor, as discussed in the Effect of Exploration on Alternative
Approaches section. The preponderance of data documents a
much higher operative mortality than was assumed in the
mathematical model.1–7 In addition, the actual data for out-
comes are dependent on details of the patient cohort, as is
discussed in this review. An admitted limitation of the math-
ematical modeling was that estimates for the various treat-
ment approaches were derived using different patient co-
horts.89 Finally, the mathematical model lumps all surprise
N2 patients together, whereas the data reviewed here leads to
the conclusion that poorly staged patients (“ignored N2”)
should not be subjected to an exploratory thoracotomy in the
first place, whereas well-staged patients should be resected
even if “unsuspected N2” involvement is found.
There seems to be little benefit to frozen section anal-
ysis of lymph nodes at the time of thoracotomy in patients
who are well-staged preoperatively. This follows from the
conclusion that no specific characteristics of N2 involvement
preclude proceeding with resection. The role of frozen sec-
tion is primarily to demonstrate tumor that cannot be re-
sected. An argument can be made that a surprise N2 node by
frozen section indicates that a MLND should be done if this
was not already planned.
In summary, careful preoperative staging is important, and
resection as the first step for patients with cN2 disease does not
seem justified. If unanticipated N2 involvement is encountered
in a well-staged patient, resection is justified unless it is apparent
that disease will be left behind. This seems to be reasonable even
in the face of negative prognostic factors. Resection of patients
with pN2 disease should probably include a formal MLND,
although conclusive data to prove this are not available. Adju-
vant therapy should be given, with the data being most clear for
adjuvant chemotherapy.
ACKNOWLEDGMENTS
I acknowledge the helpful suggestions and critique
offered by Tomasz Grodzki, MD, Robert Cerfolio, MD, and
Mark K. Ferguson, MD.
Journal of Thoracic Oncology • Volume 3, Number 3, March 2008 Intraoperative Management of Patients with NSCLC
Copyright © 2008 by the International Association for the Study of Lung Cancer 299
REFERENCES
1. Kiser AC, Detterbeck FC. General aspects of surgical treatment. In FC
Detterbeck, MP Rivera, MA Socinski, et al. (Eds.), Diagnosis and
Treatment of Lung Cancer: An Evidence-Based Guide for the Practic-
ing Clinician. Philadelphia, PA:W.B. Saunders, 2001. Pp. 133–147.
2. Kohman LJ, Meyer JA, Ikins PM, et al. Random versus predictable
risks of mortality after thoracotomy for lung cancer. J Thorac Cardio-
vasc Surg 1986;9:551–554.
3. Deneffe G, Lacquet LM, Verbeken E, et al. Surgical treatment of
bronchogenic carcinoma: a retrospective study of 720 thoracotomies.
Ann Thorac Surg 1988;45:380–383.
4. Duque JL, Ramos G, Castrodeza J, et al. Early complications in
surgical treatment of lung cancer: a prospective, multicenter study. Ann
Thorac Surg 1997;63:944–950.
5. Van den Bosch JMM, Gelissen HJ, Wagenaar SS. Exploratory thora-
cotomy in bronchial carcinoma. J Thorac Cardiovasc Surg 1983;85:
733–737.
6. Steinbaum SS, Uretzky ID, McAdams HP, et al. Exploratory thoracot-
omy for nonresectable lung cancer. Chest 1995;107:1058–1061.
7. Rami-Porta R, Mateu-Navarro M, Freixinet J, et al. Type of resection
and prognosis in lung cancer. Experience of a multicentre study. Eur
J Cardiothorac Surg 2005;28:622–628.
8. Fang D, Zhang D, Huang G, et al. Results of surgical resection of
patients with primary lung cancer: a retrospective analysis of 1,905
cases. Ann Thorac Surg 2001;72:1155–1159.
9. Watanabe S, Asamura H, Suzuki K, et al. Recent results of postoper-
ative mortality for surgical resections in lung cancer. Ann Thorac Surg
2004;78:999–1002, discussion 1002–1003.
10. Allen MS, Darling G, Pechet T, et al. Morbidity and mortality of major
pulmonary resections in patients with early-stage lung cancer: initial
results of the randomized, prospective ACOSOG Z0030 trial. Ann
Thorac Surg 2006;81:1013–1020.
11. Dales RE, Belanger R, Shamji FM, et al. Quality-of-life following
thoracotomy for lung cancer. J Clin Epidemiol 1994;47:1443–1449.
12. No˜u E, Aberg T. Quality of survival in patients with surgically treated
bronchial carcinoma. Thorax 1980;35:255–263.
13. Detterbeck F, Socinski MA, Gettinger S. Lung neoplasms. In J Norton,
PS Barie, RR Bollinger, et al. (Eds.), Surgery: Basic Science and
Clinical Evidence. New York: Springer-Verlag, 2008. In press.
14. Wang J, Olak J, Ultmann RE, et al. Assessment of pulmonary compli-
cations after lung resection. Ann Thorac Surg 1999;67:1444–1447.
15. Boysen PG, Harris JO, Block AJ. Prospective evaluation for pneumo-
nectomy using perfusion scanning: follow-up beyond one year. Chest
1981;80:163–166.
16. Zieren HU, Muller JM, Hamberger U, et al. Quality of life after
surgical therapy of bronchogenic carcinoma. Eur J Cardiothorac Surg
1996;10:233–237.
17. Myrdal G, Valtysdottir S, Lambe M, et al. Quality of life following
lung cancer surgery. Thorax 2003;58:194–197.
18. Handy JR Jr, Asaph JW, Skokan L, et al. What happens to patients
undergoing lung cancer surgery? Outcomes and quality of life before
and after surgery. Chest 2002;122:21–30.
19. Detterbeck F, Jantz M, Wallace M, et al. Invasive mediastinal staging
of lung cancer: ACCP evidence-based clinical practice guidelines (2nd
edition). Chest 2007;132:202S–220S.
20. Detterbeck F. Integration of mediastinal staging techniques for lung
cancer. Semin Thorac Cardiovasc Surg 2007;19:217–224.
21. Naruke T. Significance of lymph node metastases in lung cancer. Semin
Thorac Cardiovasc Surg 1993;5:210–218.
22. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy
in pretreatment staging of patients with primary lung cancer. Ann
Thorac Surg 1985;40:556–560.
23. Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive
superior mediastinal nodes identified at mediastinoscopy in patients
with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;
83:1–11.
24. Suzuki K, Nagai K, Yoshida J, et al. The prognosis of surgically
resected N2 non-small cell lung cancer: the importance of clinical N
status. J Thorac Cardiovasc Surg 1999;118:145–153.
25. Re´gnard JF, Magdeleinat P, Azoulay D, et al. Results of resection for
bronchogenic carcinoma with mediastinal lymph node metastases in
selected patients. Eur J Cardiothorac Surg 1991;5:583–587.
26. Nakanishi R, Osaki T, Nakanishi K, et al. Treatment strategy for
patients with surgically discovered N2 stage IIIA non-small cell lung
cancer. Ann Thorac Surg 1997;64:342–348.
27. Vansteenkiste JF, DeLeyn PR, Deneffe GJ, et al. Survival and prog-
nostic factors in resected N2 non-small cell lung cancer: a study of 140
cases. Ann Thorac Surg 1997;63:1441–1450.
28. Miller DL, McManus KG, Allen MS, et al. Results of surgical resection
of patients with N2 non-small cell lung cancer. Ann Thorac Surg
1994;57:1095–1101.
29. Andre F, Grunenwald, D, Pignon JP, et al. Survival of patients with
resected N2 non small cell lung cancer (NSCLC): heterogeneity of
prognosis and evidences for a subclassification (Abstract). J Clin Oncol
2000;18:2981–2989.
30. Maggi G, Casadio C, Cianci R, et al. Results of surgical resection of
stage IIIA (N2) non small cell lung cancer, according to the site of the
mediastinal metastases. Int Surg 1993;78:213–217.
31. Riquet M, Manac’h D, Saab M, et al. Factors determining survival in
resected N2 lung cancer. Eur J Cardiothorac Surg 1995;9:300–304.
32. Watanabe Y, Hayashi Y, Shimizu J, et al. Mediastinal nodal involve-
ment and the prognosis of non-small cell lung cancer. Chest 1991;100:
422–428.
33. Thomas PA, Piantadosi S, Mountain CF. Should subcarinal lymph
nodes be routinely examined in patients with non-small cell lung
cancer? J Thorac Cardiovasc Surg 1988;95:883–887.
34. Tanaka F, Yanagihara K, Ohtake Y, et al. Time trends and survival
after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC).
Eur J Cardiothorac Surg 1997;12:372–379.
35. Watanabe Y, Shimizu J, Oda M, et al. Aggressive surgical intervention
in N2 non-small cell cancer of the lung. Ann Thorac Surg 1991;51:
253–261.
36. Ishida T, Tateishi M, Kaneko S, et al. Surgical treatment of patients
with nonsmall-cell lung cancer and mediastinal lymph node involve-
ment. J Surg Oncol 1990;43:161–166.
37. van Klaveren RJ, Festen J, Otten HJAM, et al. Prognosis of unsus-
pected but completely resectable N2 non-small cell lung cancer. Ann
Thorac Surg 1993;56:300–304.
38. Little AG, Rusch V, Bonner J, et al. Patterns of surgical care of lung
cancer patients. Ann Thorac Surg 2005;80:2051–2056.
39. Zielinski M. Transcervical extended mediastinal lymphadenectomy:
results of staging in two hundred fifty-six patients with non-small cell
lung cancer. J Thorac Oncol 2007;2:370–372.
40. Detterbeck FC, Jones DR. Surgical treatment of stage IIIa (N2) non-
small cell lung cancer. In FC Detterbeck, MP Rivera, MA Socinski, et
al. (Eds.), Diagnosis and Treatment of Lung Cancer: An Evidence-
Based Guide for the Practicing Clinician, Philadelphia, PA: W. B.
Saunders, 2001. Pp. 244–256.
41. Goldstraw P, Mannam GC, Kaplan DK, et al. Surgical management of
non-small-cell lung cancer with ipsilateral mediastinal node metastasis
(N2 disease). J Thorac Cardiovasc Surg 1994;107:19–28.
42. De Leyn P, Schoonooghe P, Deneffe G, et al. Surgery for non-small
cell lung cancer with unsuspected metastasis to ipsilateral mediastinal
or subcarinal nodes (N2 disease). Eur J Cardiothorac Surg 1996;10:
649–655.
43. Watanabe S-I, Ladas G, Goldstraw P. Inter-observer variability in
systematic nodal dissection: comparison of European and Japanese
nodal designation. Ann Thorac Surg 2002;73:245–248.
44. Zielinski M, Rami-Porta R. Proposals for changes in the Mountain and
Dresler mediastinal and pulmonary lymph node map. J Thorac Oncol
2007;2:3–6.
45. Martini N, Flehinger BJ, Zaman MB, et al. Results of resection in
non-oat cell carcinoma of the lung with mediastinal lymph node
metastases. Ann Surg 1983;198:386–397.
46. Ichinose Y, Kato H, Koike T, et al. Overall survival and local recur-
rence of 406 completely resected stage IIIa-N2 non-small cell lung
cancer patients: questionnaire survey of the Japan Clinical Oncology
Group to plan for clinical trials. Lung Cancer 2001;34:29–36.
47. Mountain CF. Expanded possibilities for surgical treatment of lung
cancer: survival in stage IIIa disease. Chest 1990;97:1045–1051.
48. Wada H, Tanaka F, Yanagihara K, et al. Time trends and survival after
Detterbeck Journal of Thoracic Oncology • Volume 3, Number 3, March 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer300
operations for primary lung cancer from 1976 through 1990. J Thorac
Cardiovasc Surg 1996;112:349–355.
49. Rusch VW, Crowley J, Giroux D, et al. The IASLC Lung Cancer
Staging Project: proposals for the revision of the N descriptors in the
forthcoming seventh edition of the TNM classification for lung cancer.
J Thorac Oncol 2007;2:603–612.
50. Vansteenkiste JF, DeLeyn PR, Deneffe GJ, et al. Clinical prognostic
factors in surgically treated stage IIIA-N2 non-small cell lung cancer:
analysis of the literature. Lung Cancer 1998;19:3–13.
51. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic
disease in subaortic lymph nodes. Ann Thorac Surg 1987;43:155–159.
52. Sakao Y, Miyamoto H, Yamazaki A, et al. The spread of metastatic
lymph nodes to the mediastinum from left upper lobe cancer: results of
superior mediastinal nodal dissection through a median sternotomy.
Eur J Cardiothorac Surg 2006;30:543–547.
53. Okada M, Tsubota N, Yoshimura M, et al. Prognosis of completely
resected pN2 non-small cell lung carcinomas: what is the significant
node that affects survival? J Thorac Cardiovasc Surg 1999;118:270–
275.
54. Maggi G. Results of radical treatment of stage IIIa non-small-cell
carcinoma of the lung. Eur J Cardiothorac Surg 1988;2:329–335.
55. Cybulsky IJ, Lanza LA, Ryan MB, et al. Prognostic significance of
computed tomography in resected N2 lung cancer. Ann Thorac Surg
1992;54:533–537.
56. Detterbeck FC, Egan TM. Surgery for stage II non-small cell lung
cancer. In FC Detterbeck, MP Rivera, MA Socinski, et al. (Eds.),
Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide
for the Practicing Clinician, Philadelphia PA: W. B. Saunders 2001;
191–197.
57. Van Schil PE, de la Riviere AB, Knaepen PJ, et al. TNM staging and
long-term follow-up after sleeve resection for bronchogenic tumors.
Ann Thorac Surg 1991;52:1096–1101.
58. Mehran RJ, Deslauriers J, Piraux M, et al. Survival related to nodal
status after sleeve resection for lung cancer. J Thorac Cardiovasc Surg
1994;107:576–583.
59. Naruke T. Bronchoplastic and bronchovascular procedures of the
tracheobronchial tree in the management of primary lung cancer. Chest
1989;96:53S–56S.
60. Gaissert HA, Mathisen DJ, Moncure AC, et al. Survival and function
after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg
1996;111:948–953.
61. Rendina EA, Venuta F, De Giacomo T. Sleeve resection and prosthetic
reconstruction of the pulmonary artery for lung cancer. Ann Thorac
Surg 1999;68:995–1002.
62. Okada M, Yamagishi H, Satake S, et al. Survival related to lymph node
involvement in lung cancer after sleeve lobectomy compared with
pneumonectomy. J Thorac Cardiovasc Surg 2000;119:814–819.
63. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for
intraoperative lymph node staging in non-small cell lung cancer. Eur
J Cardiothorac Surg 2006;30:787–792.
64. Gaer JAR, Goldstraw P. Intraoperative assessment of nodal staging at
thoracotomy for carcinoma of the bronchus. Eur J Cardiothorac Surg
1990;4:207–210.
65. Bollen ECM, van Duin CJ, Theunissen PHMH, et al. Mediastinal
lymph node dissection in resected lung cancer: morbidity and accuracy
of staging. Ann Thorac Surg 1993;55:961–966.
66. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical system-
atic mediastinal lymphadenectomy in patients with resectable non-
small cell lung cancer. Ann Surg 1998;227:138–144.
67. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection
for clinically diagnosed peripheral non-small-cell lung cancer less than
2 cm in diameter. World J Surg 1998;22:290–294.
68. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic
nodal dissection in resectable non-small cell lung cancer. Lung Cancer
2002;36:1–6.
69. Robinson L, Ruckdeschel J, Wagner H, et al. Treatment of non-small
cell lung cancer—stage IIIA: ACCP evidence-based guidelines (2nd
edition) Chest 2007;132:243S–265S.
70. Scott W, Howington J, Feigenberg S, et al. Treatment of non-small cell
lung cancer—stage I & II: ACCP evidence-based clinical practice
guideline (2nd edition) Chest 2007;132:234S–242S.
71. Izbicki JR, Passlick B, Karg O, et al. Impact on radical systematic
mediastinal lymphadenectomy on tumor staging in lung cancer. Ann
Thorac Surg 1995;59:209–214.
72. Manser R, Wright G, Hart D, et al. Surgery for early stage non-small
cell lung cancer. Cochrane Database Syst Rev 2005;25:CD004699.
73. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissec-
tion improves survival in patients with stages II and IIIa non-small cell
lung cancer; from the Eastern Cooperative Oncology Group. Ann
Thorac Surg 2000;70:358–365.
74. Funatsu T, Matsubara Y, Ikeda S, et al. Preoperative mediastinoscopic
assessment of N factors and the need for mediastinal lymph node
dissection in T1 lung cancer. J Thorac Cardiovasc Surg 1994;108:321–
328.
75. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in
resectable non-small cell lung cancer with (neo)adjuvant chemother-
apy: results of a meta-analysis of the literature. Lung Cancer 2005;49:
13–23.
76. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected stage
IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International
Trialist Association [ANITA]): a randomised controlled trial. Lancet
Oncol 2006;7:719–727.
77. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in
non-small-cell lung cancer: systemic review and meta-analysis of
individual patient data from nine randomised controlled trials. Lancet
1998;352:257–263.
78. Socinski MA, Detterbeck FC, Rosenman JG. Adjuvant therapy of
resected non-small cell lung cancer. In FC Detterbeck, MP Rivera, MA
Socinski, et al. (Eds.), Diagnosis and Treatment of Lung Cancer: An
Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA:
W. B. Saunders, 2001. Pp. 206–219.
79. Okawara G, Ung YC, Markman BR, et al. Postoperative radiotherapy
in stage II or IIIA completely resected non-small cell lung cancer: a
systematic review and practice guideline. Lung Cancer 2004;44:1–11.
80. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy
for stage II or III non-small-cell lung cancer using the surveillance,
epidemiology, and end results database. J Clin Oncol 2006;24:2998–
3006.
81. Hensing TA, Halle JS, Socinki MA. Chemoradiotherapy for stage IIIa,
b non-small cell lung cancer. In FC Detterbeck, MP Rivera, MA
Socinski, et al. (Eds.), Diagnosis and Treatment of Lung Cancer: An
Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA:
W. B. Saunders, 2001. Pp. 291–303.
82. Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung
cancer—stage IIIb: ACCP evidenced-based clinical practice guidelines.
Chest 2007;132:266S–276S.
83. Albain K, Scott CB, Rusch VR, et al. Phase III comparison of
concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT fol-
lowed by surgical resection for stage IIIA(pN2) non-small cell lung
cancer (NSCLC): initial results from intergroup trial 0139 (RTOG
93–09) (Abstract). Proc Am Soc Clin Oncol 2003;22:621.
84. West H, Albain KS. Current standards and ongoing controversies in the
management of locally advanced non-small cell lung cancer. Semin
Oncol 2005;32:284–292.
85. Detterbeck FC, Socinski MA. Induction therapy and surgery for I–IIIa,
b non-small cell lung cancer. In FC Detterbeck, MP Rivera, MA
Socinski, et al. (Eds.), Diagnosis and Treatment of Lung Cancer: An
Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA:
W. B. Saunders, 2001. Pp. 257–266.
86. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal
thoracic radiation therapy with induction and concurrent carboplatin/
paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma.
Cancer 2001;92:1213–1223.
87. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent
chemotherapy with high-dose thoracic conformal radiation therapy in
unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-
escalation phase I trial. J Clin Oncol 2004;22:4341–4350.
88. Alam N, Sheherd F, Winton T, et al. Compliance with post-operative
adjuvant chemotherapy in non-small cell lung cancer: an analysis of
National Cancer Institute of Canada and intergroup trial JBR. 10 and a
review of the literature. Lung Cancer 2005;47:385–394.
89. Ferguson MK. Optimal management when unsuspected N2 nodal
Journal of Thoracic Oncology • Volume 3, Number 3, March 2008 Intraoperative Management of Patients with NSCLC
Copyright © 2008 by the International Association for the Study of Lung Cancer 301
disease is identified during thoracotomy for lung cancer: cost-effec-
tiveness analysis. J Thorac Cardiovasc Surg 2003;126:1935–1942.
90. Maggi G, Casadio C, Mancuso M, et al. Resection and radical lymph-
adenectomy for lung cancer: prognostic significance of lymphatic
metastases. Int Surg 1990;75:17–21.
91. Inoue M, Sawabata N, Takeda S, et al. Results of surgical intervention
for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis
predicted by complete resection in patients with single N2 disease with
primary tumor in the upper lobe. J Thorac Cardiovasc Surg 2004;127:
1100–1106.
92. Rea F, Marulli G, Callegaro D, et al. Prognostic significance of main
bronchial lymph nodes involvement in non-small cell lung carcinoma:
N1 or N2? Lung Cancer 2004;45:215–220.
93. Iwasaki A, Shirakusa T, Miyoshi T, et al. Prognostic significance of
subcarinal station in non-small cell lung cancer with T1–3 N2 disease.
Thorac Cardiovasc Surg 2006;54:42–46.
94. Okada M, Tsubota N, Yoshimura M, et al. Evaluation of TMN
classification for lung carcinoma with ipsilateral intrapulmonary me-
tastasis. Ann Thorac Surg 1999;68:326–331.
95. Conill C, Astudillo J, Verger E. Prognostic significance of metastases
to mediastinal lymph node levels in resected non-small cell lung
carcinoma. Cancer 1993;72:1199–1202.
96. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in resected
pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg
Oncol 2004;11:612–618.
97. Ohta Y, Shimizu Y, Minato H, et al. Results of initial operations in
non–small cell lung cancer patients with single-level N2 disease. Ann
Thorac Surg 2006;81:427–433.
98. Daly BDT, Mueller JD, Faling LJ, et al. N2 lung cancer: outcome in
patients with false-negative computed tomographic scans of the chest.
J Thorac Cardiovasc Surg 1993;105:904–911.
99. Sakao Y, Miyamoto H, Yamazaki A, et al. Prognostic significance of
metastasis to the highest mediastinal lymph node in nonsmall cell lung
cancer. Ann Thorac Surg 2006;81:292–297.
100. Ichinose Y, Kato H, Koike T, et al. Completely resected stage IIIA
non-small cell lung cancer: the significance of primary tumor location
and N2 station. J Thorac Cardiovasc Surg 2001;122:803–808.
101. Mountain CF. Surgery for stage IIIa-N2 non-small cell lung cancer.
Cancer 1994;73:2589–2598.
Detterbeck Journal of Thoracic Oncology • Volume 3, Number 3, March 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer302
